ALME Stock Overview
A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Almirall, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €9.59 |
| 52 Week High | €9.66 |
| 52 Week Low | €8.54 |
| Beta | 0.39 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -24.65% |
| 5 Year Change | -42.63% |
| Change since IPO | 41.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALME | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | -2.2% | -0.3% |
| 1Y | n/a | -3.2% | 6.1% |
Return vs Industry: Insufficient data to determine how ALME performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how ALME performed against the UK Market.
Price Volatility
| ALME volatility | |
|---|---|
| ALME Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: ALME's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine ALME's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1943 | 1,996 | Carlos Gallardo Piqué | www.almirall.com |
Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer.
Almirall, S.A. Fundamentals Summary
| ALME fundamental statistics | |
|---|---|
| Market cap | €1.94b |
| Earnings (TTM) | -€35.10m |
| Revenue (TTM) | €931.63m |
2.1x
P/S Ratio-55.3x
P/E RatioIs ALME overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALME income statement (TTM) | |
|---|---|
| Revenue | €931.63m |
| Cost of Revenue | €229.50m |
| Gross Profit | €702.13m |
| Other Expenses | €737.23m |
| Earnings | -€35.10m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 11, 2024
| Earnings per share (EPS) | -0.16 |
| Gross Margin | 75.37% |
| Net Profit Margin | -3.77% |
| Debt/Equity Ratio | 24.6% |
How did ALME perform over the long term?
See historical performance and comparison